Aaron Kantoff

This article shows a top-tier Big Pharma player providing an upfront payment of $150M in an overall up to $3B deal for an immune-oncology company in Phase 1/2 trials for treating blood cancer. This shows the potential in the near term for value creation for investors as Cell Source, Inc. turns the corner into the back half of its Phase 1/2 trial and gears up for its first off-the-shelf CAR-T trial   https://lnkd.in/gpPReJpR #AlternativeAdvisoryGroup #AAG #AlternativeInvestment #PrivateEquity #FinancialAdvisory #InvestmentOpportunities #InvestmentStrategies #FinancialGrowth #WealthManagement #BusinessAdvisory #IPO #Valuation #BusinessValuation #Capital #Funding #Exit #AccreditInvestors

4

1 Comment

When investors think your gene therapy isn't good enough... That's what Lexeo is feeling right now on LX2006 for cardiomyopathy associated with Friedreich's Ataxia. Their Ph1/2 trial saw 50% of patients (8 total in the trial) experience a reduction of 10% in left ventricular mass index. There are only a handful of companies developing therapies for Friedreich's Ataxia, let alone the heart-related components of this rare disease. While Lexeo was optimistic about the data and taking it to discuss a future pivotal study with regulators, the market was not, knocking the stock down at present ~25%. The public markets are brutal with earlier stage companies. Depending on capital needs, it can be a bit easier to not be public when you're early in development. Regardless, another piece of positive news for AAV as it slowly comes out of its winter. Lines up with our beginning of the year predictions below! https://lnkd.in/drRreSCd

57

2 Comments

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

6

$100 million to develop covalent biologics for oncology ! Enlaza Therapeutics just secured $100 million in Series A funding, led by J.P. Morgan Asset Management’s Private Capital division, to advance its covalent biologic platform for novel protein drugs, particularly in oncology. ⚗️Safer and more tolerable tumor penetration : Enlaza's War-LockTM technology creates biologic drugs that bind irreversibly to disease targets, enhancing efficacy and safety. By promoting covalency, it improves therapeutic performance, reduces systemic exposure, and allows sustained biologic effects with minimal dosing. Using proprietary amino acids, Enlaza engineers precise biological medicines with enhanced properties, offering a versatile solution across different protein-drug formats. 💊Investors : J.P. Morgan led the funding round, joined by existing investors like Frazier Life Sciences and new ones including Amgen and Regeneron's investment arms.

24

3 Comments

🌟 Candid Therapeutics: Disrupting Cancer Treatment with a $370M Splash 🌟 Hot off the $4.1 billion sale of RayzeBio to Bristol Myers Squibb, biotech trailblazer Ken Song, M.D., is back with a groundbreaking venture—Candid Therapeutics. With an impressive $370 million Series A funding, Candid Therapeutics is set to dominate the T-cell engager space, bolstered by strategic acquisitions of Vignette Bio and TRC 2004. 🔑 T-Cell Engagers: The Future of Cancer Therapy T-cell engagers are the next-gen bispecific antibodies, engineered to precisely target cancer cells. Unlike the cumbersome CAR T-cell therapies, Candid’s flagship assets, promise revolutionary cancer treatment options. 🧑‍⚕️ Meet the Dream Team Timothy Lu, M.D., Ph.D.: Chief Medical and Scientific Officer Bernie Huyghe, Ph.D.: Chief Technology Officer Arvind Kush: Chief Financial and Business Officer Candid Therapeutics is on a mission to transform the biotech landscape! #Biotech #TCell #cancer #autoimmune

4